ORLANDO, Fla., Sept. 7 Daniel B. Yarosh, PhD, Presidentand CEO AGI Dermatics, will deliver the keynote presentation at the 11thAnnual Sunscreen Symposium today in Lake Buena Vista, FL. The multi-daygathering (September 6th-9th) of cosmetic chemists is sponsored by the Floridachapter of the Society of Cosmetic Chemists. Dr. Yarosh will present "BeyondSunscreens: DNA Repair and Photoaging" to the more than 250 cosmetic chemistsfrom around the U.S. and throughout the world who are scheduled to attend.
"Photoaging in skin is an extremely complex process and the genomicrevolution has given us tools to understand UV-induced damage at the cellularlevel," said Dr. Yarosh. "Events such as the Sunscreen Symposium provide aforum in which we can share knowledge and ideas with colleagues, and furtherthe sunscreen advancements around the world."
Dr. Yarosh, widely recognized as a pioneer in the science of DNA repair,is the author of more than 100 scientific papers and two dozen patents. He isan active participant in international photobiology societies and the New Yorkbiotechnology community.
AGI Dermatics founded by Dr. Yarosh in 1985, has emerged as a world leaderin DNA repair technology for skin and is best known for developingDimericine(R) (T4N5), a drug in testing for treating patients with skincancers and pre-cancers. The U.S. Food & Drug Administration recently grantedFast Track designation for Dimericine for treatment of solar and ultravioletphotosensitivity in patients with Xeroderma Pigmentosum (XP), a rare geneticdisorder that blocks the body's natural ability to repair DNA damage caused byultraviolet light.
AGI Dermatics is also the developer of Remergent, a doctor-dispensedskincare line based on the science of DNA repair.
AGI Dermatics is the bio-pharmaceutical laboratory that has led theresearch of DNA repair of the skin for more than 20 years. Founded by DanielB. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicatingresearch and development to DNA repair, solar impact on the immune system, andcell-signaling in skin. The company's application of groundbreaking activeingredients and meticulously engineered liposome delivery systems is validatedin controlled clinical studies and published in dozens of peer-reviewedscientific and medical journals. www.agiderm.com
SOURCE AGI Dermatics